In an additional cohort of 124 AML/M2 patients (Appendix Table S5), THAP10 mRNA levels were 0.9‐fold lower in AML1‐ETO+ than AML1‐ETO− cases (Fig 2D). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.